2333 GMT - Licensing income from the Daybue treatment for Rett Syndrome alone supports Neuren Pharmaceuticals's share price, meaning investors effectively get exposure to its next drug candidate "for free," Bell Potter says. Neuren is upbeat about the potential of NNZ-2591 as a treatment of several neurodevelopmental disorders. It has cited positive results from Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Still, Bell Potter says it will be two years until Neuren's next major clinical catalyst: the first Phase 3 trial results for NNZ-2591. "Neuren has unrivalled balance sheet strength to prosecute future NNZ-2591 development yet effectively zero value is currently attributed to this asset, likely due to the Phase 3 readout timing," analyst Thomas Wakim says. Bell Potter retains a "buy" call on Neuren. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 11, 2025 19:33 ET (23:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。